SMS Pharmaceuticals has successfully completed its Hyderabad’s testing facility regulatory inspection by the US drug regulator.
The United States Food and Drug Administration (USFDA) audited SMS Pharmaceuticals (Central Laboratory Analytical Services) from 2nd to 6th March 2020. The regulatory audit led to zero findings. The Central Laboratory Analytical Services is a testing laboratory which works independently. This was the 1st USFDA inspection ending with zero observations, the company stated in a statement.
The company commented that it is focused on meeting the highest quality standards and is further concentrating to full compliance with Good Laboratory Practice (GLP) regulations and Current Good Manufacturing Practice (cGMP) at all its analytical facilities and manufacturing.
SMS Pharmaceuticals is involved in the sale and manufacturing of active pharmaceutical ingredients (APIs) and their intermediates. The principal products/services of firm include pharmaceuticals. The product range of company includes API and intermediates.
Copyright © 2021 Institute of Good Manufacturing Practices India ( IGMPI® All Rights Reserved. Trademarks are the property of the owner )